Objective
The current SARS-Cov-2 pandemic has brought the world to a standstill. Research groups and drug developers all over the world are scrambling to develop antivirals and vaccines to treat or prevent COVID-19. Longer term, better modeling will be required to test compounds in a controlled clinical setting once the pandemic has abated. Such a model could be a human challenge trial, commonly known as a controlled human infection model, or CHIM.
A coronavirus CHIM could be an ideal tool to support endeavors to develop effective COVID-19 interventions and provide a longer-term platform to support preparations against the emergence of new or novel coronaviruses.
This webinar will highlight the regulatory considerations to implement such a model and speed up the development pathway of much needed drugs and antiviral products.Join SGS experts and explore the potential of CHIM, COVID-19 regulatory considerations, working with regulators and how to accelerate your pipeline.
Agenda
- Introduction to controlled human infection modeling (CHIM)
- SARS-CoV-2: an introduction
- Regulatory considerations surrounding COVID-19 modeling
- Working with regulators on COVID-19 CHIM design and development
- How a COVID-19 CHIM trial could accelerate your pipeline development
- Q&A
Speakers
Bruno Speder – Head Clinical Regulatory Affairs & Consultancy, SGS
Adrian Wildfire – Scientific Director, SGS
Robin Rogiers - Investigator, SGS
